119 related articles for article (PubMed ID: 37806058)
41. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
42. Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents.
Dung do TM; Dung PT; Oanh DT; Hai PT; Huong le TT; Loi VD; Hahn H; Han BW; Kim J; Han SB; Nam NH
Med Chem; 2015; 11(8):725-35. PubMed ID: 26133355
[TBL] [Abstract][Full Text] [Related]
43. A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study.
Huang D; Li X; Wei Y; Xiu Z
Eur J Med Chem; 2012 Jun; 52():111-22. PubMed ID: 22465091
[TBL] [Abstract][Full Text] [Related]
44. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
45. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
46. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
[TBL] [Abstract][Full Text] [Related]
47. Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: Histone deacetylases inhibitory activity and molecular docking study.
Hamdi A; Elhusseiny WM; Othman DIA; Haikal A; Bakheit AH; El-Azab AS; Al-Agamy MHM; Abdel-Aziz AA
Eur J Med Chem; 2022 Dec; 244():114827. PubMed ID: 36242988
[TBL] [Abstract][Full Text] [Related]
48. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
49. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
[TBL] [Abstract][Full Text] [Related]
50. Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
Cincinelli R; Zwick V; Musso L; Zuco V; De Cesare M; Zunino F; Simoes-Pires C; Nurisso A; Giannini G; Cuendet M; Dallavalle S
Eur J Med Chem; 2016 Apr; 112():99-105. PubMed ID: 26890116
[TBL] [Abstract][Full Text] [Related]
51. Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
Zhang L; Kang W; Lu X; Ma S; Dong L; Zou B
Gene; 2019 Jan; 681():15-25. PubMed ID: 30266498
[TBL] [Abstract][Full Text] [Related]
52. HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer.
Hu XT; Xing W; Zhao RS; Tan Y; Wu XF; Ao LQ; Li Z; Yao MW; Yuan M; Guo W; Li SZ; Yu J; Ao X; Xu X
J Exp Clin Cancer Res; 2020 Dec; 39(1):270. PubMed ID: 33267897
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
[TBL] [Abstract][Full Text] [Related]
54. Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.
Ibrahim HS; Abdelsalam M; Zeyn Y; Zessin M; Mustafa AM; Fischer MA; Zeyen P; Sun P; Bülbül EF; Vecchio A; Erdmann F; Schmidt M; Robaa D; Barinka C; Romier C; Schutkowski M; Krämer OH; Sippl W
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008795
[TBL] [Abstract][Full Text] [Related]
55. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Choubey SK; Jeyaraman J
J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
[TBL] [Abstract][Full Text] [Related]
56. Virtual screening and experimental validation of novel histone deacetylase inhibitors.
Huang YX; Zhao J; Song QH; Zheng LH; Fan C; Liu TT; Bao YL; Sun LG; Zhang LB; Li YX
BMC Pharmacol Toxicol; 2016 Jul; 17(1):32. PubMed ID: 27443303
[TBL] [Abstract][Full Text] [Related]
57. Patchouli alcohol, an essential oil of Pogostemon cablin, exhibits anti-tumorigenic activity in human colorectal cancer cells.
Jeong JB; Choi J; Lou Z; Jiang X; Lee SH
Int Immunopharmacol; 2013 Jun; 16(2):184-90. PubMed ID: 23602914
[TBL] [Abstract][Full Text] [Related]
58. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
59. Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases.
Berger A; Venturelli S; Kallnischkies M; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Weiss TS; Lauer UM; Bischoff SC; Bitzer M
J Nutr Biochem; 2013 Jun; 24(6):977-85. PubMed ID: 23159065
[TBL] [Abstract][Full Text] [Related]
60. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
